A+ R A-

Poster Discussion Session of Invited Abstracts

The following abstracts represent the posters presented at IWWM-8 (London-2014), Session-9:

Session Chair: G. Merlini

W1: MYD88 L265P: A target for T cell based therapy of WM J. Nielsen (Canada)

W2: Clinico-Pathological Study of WM in Far East Asia N. Sekiguchi (Japan)

W3: ABT-199 (GDC-0199) Achieves Deep and Durable Responses in Patient with Heavily Pretreated WM: Preliminary Results from an Onging Phase I Study C. Tam (Australia)

W4: The Assessment of Heavy/Light chain pairs of Immunoglobulin cannot Substitute M-protein Detection in Patients with WM D. Iveta & V. Scudla (Czech Republic)

W5: The significance of 18FDG PET/CT in patients with Newly Diagnosed WM D. Iveta & V. Scudla (Czech Republic)

W6: Bing Neel Syndrome: the French experience L. Simon (France)

W7: Rare Clinical Manifestations in WM/ LPL L. Petrikkos (Greece)

W8: Borderline Cases in between IGM MM and WM. Should Cyclin-D1 Expression be used to Guide Diagnosis? L. Petrikkos (Greece)

W9: CD19 Targeted chimeric antigen modified T-cells for the treatment of WM E.L. Smith (USA)

W10: Initial Experience and Clinical Utility of a High Resolution melting Assay to detect the MYD88 L265P in Peripheral Blood and Bone marrow Aspirates in patients with LPL and Related Disorders J. Kothari (UK)

W11: Bone Involvement in Waldenström’s Macroglobulinaemia: 2 illustrative cases J. Kothari (UK)

W12: Comparison of Capillary Zone Electropheresis and Immunoturbidimetric Methods for the Quantification of Serum Monoclonal IgM in Patients with WM J. Kothari (UK)

W13: Peripheral Bing-Neel syndrome’ and other manifestations of Waldenström’s Macroglobulinaemia-related neuropathies: keeping an open mind and pursuing the precise aetiology M. Lunn (UK)

W14: Relapsed Waldenström’s macroglobulinaemia presenting as Bing-Neel Syndrome demonstrates an excellent response to IDARAM chemotherapy S. D’Sa (UK)

W15: Interplay between MYC and NK-kB Deregulation in B Cell Tumorigenesis D. Calado (UK)

W16: IMO-8400 inhibits MYD88 L265P mediated signaling and Cell growth in WM W. Jiang (USA)

W17: Heavy/Light Chain Immunoassays Measuring IgMk and IgM? provide an Alternative Method for Quantifying monocloncal IgM immunoglobulins M. Offer (UK)

W18: Microarray and Gene Expression Profiling of IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) A Greco (Italy)

W19: CD319/CS1 Expression Patterns in WM, Myeloma and MGUS: Implications for Antibody Therapy R. de Tute (UK)

W20: Use of Multi-parametric Flow Cytometry in the Diagnosis and Monitoring of WM R. de Tute (UK)

W21: Bendamustine is a well tolerated and effective rescue agent in AL amyloidosis, particularly in patients with WM P. Milani (Italy)

W22: Multi-parameter single cell phospho-filing of the BCR signaling pathway in WMW23: Gene Expression Profiling in WM: Comparison Between Asymptomatic and Symptomatic Patients K. Argyropoulos (USA)

W23: Gene Expression Profiling in WM: Comparison Between Asymptomatic and Symptomatic Patients G. Garcia Sanz (Spain)

W24: Clinical profile of single-agent modified-release oprozomib tablets in patients with WM: updated results from a multicenter, open-label, dose escalation, phase 1b/2 study I Ghobrial (USA)

W25: Bing Neel Syndrome with good response to Low Dose oral Fludarabine in Four (4) Consecutive Patients J. Vos (the Netherlands)

W26: Population based study on the impact of familial form of WM on overall survival V. Steingrimsson (Iceland)

W27: Prognostic importance of the quality of response to first line therapy in patients with WM Guidez (France)

W28: Critical growth and survival role of miR-23b/Sp1/NFkB pathway in WM M. Gkotzamanidou (USA)

W29: Spontaneous DNA Damage and DDR pathways in WM & MM: Implications for Therapy M. Gkotzamanidou (USA)

W30: Treatment Effects on IgA and IgG Hypogammaglobulinemia in WM Z. Hunter (USA)

W31: Tumor induced immunosupression in WM and MM. Marked differences in immune homeostatic balance between tumor and host D. Joshua (Australia)

W32: Diagnostic and Prognostic Significance of Constitutive and Induced pSTAT3,pSTAT5, pAKT and pERK in Plasma Cell Disorders by Phospho Flow D. Joshua (Australia)

W33: The positive effects of one hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients HJ Kim (South Korea)

W34: Characteristics and outcomes of IgM associated systemic AL amyloidosis-analysis of a prospective study [ALChemy Study] A Wechalaker (UK)

W35: Randomized Phase 2 Trial in WM Subcutaneous BCR vs. FCR for Intial Therapy of WM: a Randomized Phase II Study R. Auer (UK)

W36: Clinical Features and Survival Outcome of Young Patients with WM J. Paludo (USA)

W37: Two cases of Bing Neel Syndrome. An ongoing diagnostic and therapeutic challenge in WM E. Hatjiharissi (Greece)

W38: A Phase 1/2 study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in sCD27 signaling in patients with relapsed or refractory Waldenström’s macroglobulinemia A Thibault (Belgium)

London 2014 (IWWM-8)


  • Shirley D'Sa MD
  • Charalampia Kyriakou MD, Ph.D
  • Roger Owen MD
  • Steven Treon MD Ph.D


Christopher Patterson


  • Kenneth C Anderson MD
  • Bart Barlogie MD Ph.D
  • Meletios Dimopoulos MD
  • Jean-Paul Fermand MD
  • Morie Gertz MD
  • Irene Ghobrial MD
  • Marie-Jose Kersten MD Ph.D
  • Eva Kimby MD Ph.D
  • Sigurdur Kristinsson MD Ph.D
  • Robert Kyle MD
  • Ola Landgren MD PhD
  • Michael Lunn MD Ph.D
  • Veronique Leblond MD
  • Giampaolo Merlini MD
  • Pierre Morel MD
  • Enrica Morra MD
  • Nikhil Munshi MD
  • Jesus San Miguel MD PhD
  • Linda Pilarski Ph.D

5th International Doctor-Patient Forum on WM, London 2014

Jointly sponsored by IWMF and WMUK. Patient Track Part of IWWM8 doctor workshop. Open to all, worldwide, including families of patients and interested medical professionals.

The 2014 International Forum is one of the most important events of 2014 for the WM community worldwide.   It comes at the end of the IWWM8 (the 8th WM International Workshop) meeting for doctors organised by the Bing Centre for WM at Harvard, and a distinguished selection of the doctors coming to London from around the world will be with us on the Sunday to present the many new advances in treatment and care of WM.  The highlight of the day is likely to be a presentation from Dr Steven Treon and his Dana-Farber team from the Bing Centre outlining the latest research and trials involving Ibrutinib (Imbruvica®), which is emerging as a breakthrough therapy in many B cell related diseases, including WM.

Please note this meeting was organized through the IWMF and WMUK.  For more information, feel free to visit the IWMF website.